1

Peripheral artery disease affects the legs of claudicating patients in a diffuse manner irrespective of the level of the arterial tree primarily involved.

- 3 Article Type: Original Paper
- 4 Todd J. Leutzinger, MS¹, Panagiotis Koutakis, PhD², Matthew A. Fuglestad, MD³, Hafizur
- 5 Rahman, PhD, Holly Despiegelaere RN⁴, Mahdi Hassan, MS, Molly Schieber, MS, Jason M.
- 6 Johanning, MD^{3,4}, Nick Stergiou, PhD^{1,5}, G. Matthew Longo, MD³, George P. Casale³, Sara A.
- 7 Myers, PhD^{1,3**}, Iraklis I. Pipinos, MD^{1,3,4**}
- 8 ¹Department of Biomechanics and Center for Research in Human Movement Variability,
- 9 University of Nebraska at Omaha, Omaha, NE
- ²Department of Biology, Baylor University, Wako, TX
- ³ Department of Surgery, University of Nebraska Medical Center, Omaha, NE
- ⁴ Department of Surgery and Research Service, Nebraska and Western Iowa Veterans Affairs
- 13 Medical Center, Omaha, NE
- ⁵Department of Environmental Agricultural and Occupational Health, University of Nebraska
- 15 Medical Center, Omaha, NE
- 16 ****** Corresponding Authors:
- 17 Sara A. Myers
- 18 6001 Dodge St, BRB 212
- 19 Omaha, NE 68182
- 20 Work Phone: (402) 554-3246
- 21 Work FAX: (402) 554-5938
- 22 Email: samyers@unomaha.edu
- 23 And
- 24 Iraklis Pipinos, MD
- 25 University of Nebraska Medical Center
- 26 Work Phone: 402.559.9549
- 27 Email: ipipinos@unmc.edu
- 28
- 29 Key Words: peripheral artery disease, vascular stenosis, vascular narrowing, gait biomechanics,
- 30 walking

2

31 ABSTRACT

Objective: Different levels of arterial occlusive disease (aortoiliac, femoropopliteal, multi-level disease) can produce claudication symptoms in different leg muscle groups (buttocks, thighs, calves) in patients with peripheral artery disease (PAD). We tested the hypothesis that different levels of occlusive disease uniquely affect the muscles of PAD legs and produce distinctive patterns in the way claudicating patients walk.

Methods: 97 PAD patients and 35 healthy controls were recruited. PAD patients were categorized to aortoiliac, femoropopliteal and multi-level disease groups using computerized tomographic angiography. Subjects performed walking trials both pain-free and during claudication and joint kinematics, kinetics, and spatiotemporal parameters were calculated to evaluate the net contribution of the calf, thigh and buttock muscles.

Results: PAD patients with different levels of arterial occlusions had different patterns of symptoms in their calves, thighs and buttocks. However, no significant biomechanical differences were found between PAD groups during the pain-free conditions with minimal differences between PAD groups in the claudicating state. All statistical differences in the pain-free condition occurred between healthy controls and one or more PAD groups. A discriminant analysis function was able to adequately predict if a subject was a control with over 70% accuracy, but the function was unable to differentiate between PAD groups.

49 Conclusions: In-depth gait analyses of claudicating PAD patients indicate that different levels of 50 arterial disease produce symptoms that affect different muscle groups across the lower extremity 51 but impact the function of the leg muscles in a diffuse manner generating similar walking 52 impairments.

3

53 INTRODUCTION

Intermittent claudication is the most common manifestation of peripheral artery disease
(PAD)[1]. Claudication is defined as walking-induced, ischemic leg pain that is most commonly
described by the patient as severe muscle cramping, tightness, aching, and/or fatigue[2].
Claudication results in severely decreased functional ability[3] and quality of life[4] and is
associated with increased risk for the occurrence of other cardiovascular related events and
mortality[5]–[7].

Patients with PAD walk with an abnormal gait pattern compared to healthy, age matched 60 controls[8], [9]. The majority of these gait abnormalities are present from the first step the 61 62 patients take, well before the onset of claudication, and become more severe when claudication discomfort begins[10], [11]. Research from our group and others has shown that the abnormal 63 gait pattern is characterized by slower walking speed, decreased cadence, increased stance time, 64 65 and shorter stride lengths compared to healthy, age-matched controls[12]. Furthermore, patients 66 with PAD walk with altered joint angles [12], [13] and reduced joint torques [10], [14] and powers[10], [14], [15] around the ankle, knee, and hip joints compared to their healthy 67 counterparts. 68

Atherosclerotic stenoses/occlusions can occur at any or multiple levels throughout the arterial tree supplying the leg, restricting blood flow to the muscles responsible for movement at the hip, knee, and ankle joints. These blockages are typically grouped into the following general levels: aortoiliac (AI), femoropopliteal (FP), tibial, and multi-level disease (MLD)[16]. Aortoiliac disease can produce claudication symptoms in all major muscle groups (calves, thighs and buttocks) of the leg [17], [18]. Femoropopliteal disease can produce claudication symptoms

4

in the muscles of the calves[17]. Tibial disease may also produce claudication symptoms in the
muscles of the calf. Multi-level atherosclerosis is associated with vascular narrowing/occlusion
in more than one level of the arterial tree of the leg. Patients with MLD tend to have worse
hemodynamic compromise, than patients with single level disease, and they can experience
claudication symptoms in all major muscle groups of the leg including those of the calves, thighs
and buttocks. However, they usually experience claudication pain distal to the most affected
arterial segment[18] [19].

Arterial blockages and the ischemia and ischemia/reperfusion they generate in the 82 muscles they affect, produce an ischemic myopathy in the legs of PAD patients. At the 83 84 histological level the principal characteristics of the myopathy are myofiber degeneration and fibrosis of the extracellular matrix and microvessels of the affected muscles[20]-[25], [64]. At 85 the biochemical level the myopathy is characterized by oxidative damage, mitochondrial 86 dysfunction, cytoskeletal disintegration and a characteristic upregulation of cytokines[20], [22], 87 [26]–[31]. The myopathy of PAD in association with exercise-induced ischemia produce the, 88 familiar to all vascular practitioners, abnormal muscle performance and metabolically inefficient 89 walking pattern of claudicating patients [10]–[12], [14], [15], [32]. Because the level of occlusive 90 disease usually determines the muscle group that is affected by the discomfort of claudication, it 91 is possible that disease level may also play a primary role in the patient's walking biomechanics 92 and determine a patient's compensation strategies during gait. Specifically, it is likely that 93 different levels of occlusive disease produce ischemia, myopathy, and functional compromise of 94 95 different muscle groups in the PAD legs which then results in distinctive gait patterns. It is also possible that as different muscle groups are affected, the patient's muscular and neurological 96 systems respond by alleviating the load placed on the more affected muscle groups while 97

5

increasing the contribution of less affected muscles in an attempt to reduce pain and improve 98 metabolic efficiency. Investigating the influence of disease level on a patient's gait may provide 99 pivotal information regarding the pathophysiology of claudication and the development of each 100 patient's walking impairments. By identifying if and how the level of vascular stenosis/occlusion 101 affects the contributions of the muscles that move particular joints, and results in specific gait 102 abnormalities in individuals with PAD, clinicians and therapists may be better able to understand 103 the type and degree of functional limitation produced by different patterns of occlusive disease. 104 This knowledge may help with the development of treatment plans that target specific muscles 105 106 such as the ankle or knee or hip flexors/extensors based on the vascular stenosis/occlusion level and may provide the basis for physical therapy and exercise interventions that are more patient-107 specific and possibly more effective in rehabilitating each patient's PAD limitations. 108

In this study we tested the hypothesis that the level of arterial stenosis/occlusion would 109 110 uniquely impair the net muscle contributions, walking pattern and overall walking ability between patients with different levels of disease and compared to healthy controls. More 111 specifically we aimed to determine if different levels of vascular stenosis/ occlusion uniquely 112 affect walking patterns, as described by objective kinematic, kinetic, spatiotemporal gait 113 parameters, and six minute walk distances and by subjective measurements acquired through the 114 Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study Short Form 36 115 Health Survey (SF-36). Furthermore, we sought to determine if claudicating patients can be 116 classified according to their level of disease based on their pattern of gait impairments. 117

118

6

120 METHODS

121 Study Participants

122	Ninety Seven patients (96 males, 1 female) diagnosed with claudication secondary to
123	PAD, age (63.34 ± 6.49 years), height (1.76 ± 0.07 m), and body-mass (87.31 ± 17.22 kg) were
124	recruited from the Nebraska and Western Iowa Veterans Affairs Medical Center and the
125	University of Nebraska Medical Center. Thirty-five healthy controls with similar age ($65.23 \pm$
126	9.51 years), height (1.74 \pm 0.08 m), and body-mass (79.90 \pm 13.80 kg) were recruited from the
127	community.

128 Inclusion and Exclusion Criteria

129 Patient inclusion criteria included the ability to provide written, informed consent for 130 study participation, a history of chronic, exercise-limiting claudication, an ABI ≤ 0.90 at rest[33], 131 [34] and stable blood pressure, lipid, and/or diabetes regimens and risk factor control for six 132 weeks or more. Patient exclusion criteria included ischemic rest pain, tissue loss due to PAD, the presence of acute lower leg ischemia and significant limitations in the ability to walk due to 133 conditions other than claudication such as pathology occurring in the leg (joint, musculoskeletal, 134 neurological), heart, or lungs. Patients were screened and evaluated by one of two board certified 135 vascular surgeons prior to study enrollment. Healthy control participants were excluded for the 136 same exclusion criteria as the PAD population or if they had walking limitations, if they 137 experienced leg pain during walking, or if their ABI values at rest were < 0.90. All controls were 138 screened by a trained member of the study team measuring systolic pressures at the brachial and 139 pedal arteries using Doppler [6]. Informed consent was obtained from all study participants prior 140

7

to data collection according to the guidelines of the institutional review boards of the twomedical centers.

143 CTA and determination of level of disease

Patients with PAD underwent computerized tomographic angiography (CTA) of the abdomen, 144 pelvis and lower extremities including delayed imaging. 1.5-mm cross-sectional images were 145 obtained from the lower chest to the toes and were used by one of two board certified vascular 146 surgeons to determine the level of disease[35] [36]. The degree of arterial stenosis was 147 considered minimal if the arterial diameter was decreased by less than 10%, mild if the arterial 148 diameter was decreased by 10 to 30%, moderate if the arterial diameter was decreased by 30% to 149 70%, and severe if the arterial diameter was decreased by more than 70%. A patient was 150 151 considered as having disease in a segment of his arterial tree if there was evidence of moderate or severe stenosis (30-100% blockage) in one or more arteries of that segment. Patients with 152 minimal (<10% diameter reduction) or mild stenosis (10-30% diameter reduction) in the arteries 153 of a particular segment were considered as not having occlusive disease in that segment. 154 Occlusive disease patterns were described as Aortoiliac (AI, stenosis/occlusion in the aorta, iliac 155 and common femoral arteries), Femoropopliteal (FP, stenosis/occlusion in the superficial femoral 156 and popliteal arteries) and multilevel disease (MLD, Aortoiliac + femoropopliteal disease). A 157 total of 26 (of 97) PAD patients had significant disease that affected one to three of their tibial 158 arteries but all of them had dominant disease in the more proximal AI or FP segments and were 159 analyzed as part of the dominant proximal segment(s) of disease. More specifically, 25 patients 160 (age: 60.67 ± 6.52 years, height: 1.77 ± 0.09 m, body mass: 90.50 ± 14.90 kg) had isolated AI 161 162 disease. Four patients in the AI group had disease in one of their tibial arteries and the rest had no appreciable tibial disease. Twenty-three patients (age: 63.57 ± 6.69 years, height: 1.75 ± 0.08 163

8

164	m, body mass: 84.20 ± 19.66 kg) had isolated FP disease. Four patients in the FP group had
165	disease in one, one had disease in two and two had disease in all three tibial arteries while the
166	rest had no appreciable tibial disease. Forty-nine patients (age: 64.55 ± 6.11 years, height; $1.75 $
167	0.05 m, body mass: 87.14 ± 17.17 kg) had MLD (combination of AI and FP disease). Eleven
168	patients in the MLD group had disease in one, three had disease in two and one in all three tibial
169	arteries while the rest had no appreciable tibial disease.

170 Experimental Procedure and Data Collection

Prior to data collection, 27 retro-reflective markers were placed at specific anatomical 171 locations on each participant's lower limbs utilizing the marker systems of Vaughan and 172 Nigg[37], [38]. To capture kinematic and kinetic gait parameters, each study participant was 173 174 instructed to walk at their preferred walking speed over a 4.5-meter walkway containing inground force platforms. Participants with PAD performed overground walking trials in both a 175 pain free and claudicating state. Each subject's most affected leg based on lowest ABI value was 176 177 used for analysis. During the pain free condition, a one-minute rest period was required between walking trials to ensure the absence of claudication; more rest was required if the participant 178 indicated pain was present. To induce the claudicating state, each participant with PAD 179 performed a six-minute walk test. For this test, participants were instructed to cover as much 180 distance as possible in six minutes, walking around two cones placed 50 feet apart inside the 181 laboratory. If the participant desired, they were able to rest during the test, but the six-minute 182 timer continued to run. Confirmation that participants were experiencing claudication was 183 obtained prior to performing the overground claudication trials. During the claudication 184 condition, study participants were not given a one-minute rest between trials, and they confirmed 185 the presence of claudication pain prior to beginning each trial. 186

9

187 Data Analysis

Quality of life measures. Overall health and physical function were assessed using the 188 WIQ[39] and SF-36[40]. The WIQ is a disease-specific questionnaire validated in patients with 189 intermittent claudication. It consists of four subcategories: pain, walking distance, walking 190 speed, and stair climbing ability. The SF-36 consists of eight health domains: physical function, 191 limitation due to physical health, limitation due to emotional health, energy/vitality, general 192 mental health, bodily pain, social function, and overall general health. The SF-36 has been 193 extensively evaluated and tested with a variety of populations and is able to distinguish between 194 groups of varying health status[41]. Both scales range from 0 to 100, with 100 being the higher 195 196 functioning/more positive health outcome score.

197 *Quantitative biomechanics measures.* The participants' lower extremity threedimensional kinematics were collected using a Motion Analysis eight-camera motion capture 198 system (Motion Analysis Corp, Santa Rosa, CA) sampling at 60Hz. Kinetic data were acquired 199 200 using one Kistler piezoelectric force platform (Kistler North America, Amherst, NY) sampling at 600Hz. Motion capture data were filtered using a low pass Butterworth filter with a cutoff 201 frequency of 5Hz. For the kinematic and kinetic data, a total of five clean foot contacts were 202 collected and averaged for each study participant in each walking condition. A clean foot contact 203 204 was defined as a step in which the foot in stance phase only came in contact with one force platform and no other contacts occurred on that platform during the walking trial. 205 206 Spatiotemporal gait parameters were calculated by averaging data from five of the overground walking trials. Because spatiotemporal gait parameters were not initially analyzed for this data, 207 208 two of the participants in the FP group and three healthy controls did not take enough steps for 209 spatiotemporal characteristics to be calculated from each of the walking trials. Data were

10

210	exported and processed using Cortex C-Motion Capture system (Motion Analysis Corporation,
211	Santa Rosa, CA), Visual 3D (Germantown, MD, USA), and personalized MATLAB (The
212	Mathworks, Inc., Natick, MA, USA) codes.

Joint kinematics and kinetics were calculated in the sagittal plane during the stance phase of walking. The stance phase can further be divided into three distinct stages: weight acceptance, single limb support, and push-off. An inverse dynamics solution was performed to calculate joint torques and powers from joint kinematics and ground reaction force data. Only data from each patient's most affected leg were analyzed, and control participants were distributed to match the ratio of right to left legs that were analyzed from the patients with PAD. Torque and power data were normalized to each participant's body mass.

220 A canonical linear discriminant function analysis (i.e., discriminant analysis) was performed to determine if differences in gait parameters could be used to distinguish between 221 different levels of disease and healthy controls. Data were checked for multicollinearity to reduce 222 223 the amount of mutual information in the model by running a bivariate Pearson's correlation for both the pain and pain free data. During the pain free condition ankle plantarflexor torque, knee 224 flexion torque, hip extension torque, ankle power absorption during weight acceptance, ankle 225 power absorption during single limb support, ankle power generation during push-off, knee 226 power generation during single limb support, hip power generation during weight acceptance, 227 228 hip power absorption during single limb support, hip power generation during push-off, ankle range of motion, hip range of motion, stride length, and stance time were included in the 229 analysis. During the pain condition, ankle dorsiflexion torque, knee flexion torque, hip extension 230 231 torque, hip flexion torque, ankle power absorption during weight acceptance, ankle power absorption during single limb support, ankle power generation during push-off, hip power 232

11

233	generation during weight acceptance, knee power absorption during push-off, ankle range of
234	motion, knee range of motion, and stride time were included in the analysis.

235 Statistical Analysis

236	Independent, one-way analysis of variance (ANOVA) tests were used to identify
237	differences between participant groups (controls, AI, FP, MLD) for SF-36 subscale scores, WIQ
238	subscale scores, and quantitative gait measures. A significant main effect indicates one or more
239	significant differences between two or more of the four groups being compared. For variables
240	with significant main effects, Bonferroni post hoc analyses were performed when necessary to
241	determine which groups were significantly different from each other. Independent samples t-tests
242	were used to compare controls to all PAD patients pooled in a single group. A discriminant
243	analysis was performed for each walking condition to determine if gait impairments were able to
244	distinguish between patients with different levels of disease and healthy controls and determine
245	which gait variables were most useful in this calculation. All analyses were performed using
246	SPSS 23 statistical software (SPSS Inc., Chicago, Ill) with an alpha level set to 0.05.
247	
248	
249	
250	
251	
252	
253	
254	
255	

12

256 **RESULTS**

257 *Demographics*

258	Demographic and anthropometric data for each participating group can be found in Table
259	I. There was not a significant between-groups effect of age, height, body mass, or body mass
260	index. Ankle brachial index was significantly different between patient groups for both the most
261	affected (p < 0.001) and least affected leg (p < 0.001). Patients with MLD had significantly
262	lower ABI values in both the most and least affected legs compared to the AI (most affected: $p <$
263	0.001, least affected: $p < 0.001$) and FP (most affected: $p = 0.019$, least affected: $p = 0.015$)
264	groups. Of the 25 patients with AI disease eight had mild, eleven minimal, and six no FP
265	occlusive disease. Three of the patients with AI disease presented with calf claudication, five
266	with thigh and calf, six with buttock and calf, nine with buttock, thigh, and calf, and two with
267	buttock and thigh symptoms. Of the 23 patients with FP disease eleven had mild, nine minimal,
268	and three no AI occlusive disease (two of these three patients had mildly ectatic AI segment). All
269	23 patients with FP disease presented with calf only claudication. All 49 MLD patients had
270	combination of AI and FP disease. Fifteen presented with calf claudication, thirteen with thigh
271	and calf, six with buttock and calf, fourteen with buttock, thigh, and calf, and one with buttock-
272	only symptoms.

273 INSERT TABLE I ABOUT HERE

274 *Questionnaire comparisons between healthy controls and PAD groups*

275 When comparing WIQ subscale scores across participant groups, there were significant 276 main effects for each of the four subscale categories (WIQ Pain: p < 0.001, WIQ Distance: p <277 0.001, WIQ Speed: p < 0.001, WIQ Stairs: p < 0.001; Table II). Healthy control participants had

13

significantly higher WIQ scores across all four subscales when independently compared to eachpatient group (Table II).

280 INSERT TABLE II ABOUT HERE

When comparing SF-36 subscale scores across participant groups, significant main 281 effects were present for physical function (p < 0.001), limitations due to physical health (p < 0.001) 282 0.001), limitations due to emotional health (p = 0.002), energy (p < 0.001), emotional health (p < 283 (0.001), pain (p < 0.001), social function (p < 0.001) and general function (p < 0.001; Table III). 284 Post-hoc tests revealed control participants had significantly higher SF-36 scores in independent 285 286 comparisons to each level of disease group for all subscales except the emotional health subscale where the AI group did not differ from healthy controls (Table III). This indicates healthy 287 288 controls had better functioning that all PAD groups for nearly all health domains assessed by the SF-36. In the emotional health subscale, the AI group scored higher than the MLD group (p =289 0.004), indicating better emotional health for those with AI level disease. In the pain subscale the 290 291 MLD group scored significantly higher than the FP group (p = 0.009), meaning the MLD group subjectively had less pain than the FP group. 292

- 293 INSERT TABLE III ABOUT HERE
- 294 Pain free walking: healthy controls versus PAD groups

There were significant main effects between participant groups for kinematic and kinetic gait parameters when walking in the pain-free condition for 12 of the 18 biomechanics measures (ankle dorsiflexor torque: p = 0.004, knee extensor torque: p = 0.006, hip extension torque: p < 0.001, hip flexor torque: p < 0.001, ankle power absorption during weight acceptance: p < 0.001, ankle power generation during push-off: p < 0.001, knee power absorption during weight

14

300	acceptance: $p = 0.013$, knee power generation during single limb support: $p = 0.002$, knee power
301	absorption during push-off: $p < 0.001$, hip power absorption during single limb support: $p =$
302	0.001, hip power generation during push-off: $p < 0.001$, hip range of motion: $p = 0.003$; Table
303	IV). The six variables that did not have significant differences during pain free walking included:
304	ankle plantarflexor torque during push-off, knee flexor torque during single limb support, ankle
305	power absorption during single limb support, hip power generation during weight acceptance,
306	ankle range of motion, and knee range of motion (Table IV). There were similar significant main
307	effects for spatiotemporal gait parameters during pain free walking, with seven of the eight
308	dependent variables demonstrating significant differences (step length: $p < 0.001$, stride length: p
309	< 0.001, walking velocity: p < 0.001 , stance time: p < 0.001 , stride time: p $= 0.002$, step width: p
310	= 0.006, cadence: $p = 0.001$) Only swing time did not have a significant main effect during pain
311	free walking (Table V).

The post-hoc analysis revealed that all differences occurred between one or more level of disease groups and healthy controls. Bonferroni post hoc analyses indicated no differences for kinematic, kinetic, or spatiotemporal gait parameters between PAD level of disease groups when walking in the pain free condition. Of the total 26 gait comparisons (18 kinematic/kinetic and 8 spatiotemporal), the differences between healthy controls and all PAD groups occurred for 20 of 26 variables, patients with AI level disease for 12 of 26 variables, patients with FP for 15 of 26 variables, and patients with MLD for 20 of 26 variables (Tables IV and V).

319 INSERT TABLES IV AND V ABOUT HERE

320 *Pain walking: healthy controls versus PAD groups*

15

321	When walking in the pain condition, there were significant main effects of participant
322	group for 14 of 18 kinematic and kinetic gait parameters (ankle dorsiflexor torque: $p < 0.001$,
323	ankle plantarflexor torque: p < 0.001, knee extensor torque: p = 0.008, hip extension torque: p <
324	0.001, hip flexor torque: p< 0.001, ankle power absorption during weight acceptance: p < 0.001,
325	knee power absorption during weight acceptance: $p = 0.007$, knee power generation during
326	single limb support: $p = 0.005$, hip power absorption during single limb support: $p = 0.003$, ankle
327	power generation during push-off: $p < 0.001$, knee power absorption during push-off: $p < 0.001$,
328	hip power generation during push-off: $p < 0.001$, ankle range of motion: $p = 0.002$, hip range of
329	motion: $p < 0.001$). The four variables that did not show a significant main effect were knee
330	flexor torque during single limb support, hip power generation during weight acceptance, ankle
331	power absorption during single limb support, and knee range of motion (Table VI). There were
332	also significant main effects for eight spatiotemporal gait parameters (step length: $p < 0.001$,
333	stride length: $p < 0.001$, walking velocity: $p < 0.001$, stance time: $p < 0.001$, stride time: $p =$
334	0.006, step width: $p = 0.009$) Swing time and cadence did not show a significant main effect
335	(Table VII).

336 Bonferroni post hoc analyses indicated no differences for kinematic, kinetic, or spatiotemporal gait parameters between any PAD level of disease groups when walking in the 337 pain condition except two differences. Those differences include the MLD group, which had a 338 significantly larger ankle power absorption during weight acceptance compared to the FP group 339 (p = 0.003), and the AI group produced significantly more ankle power during push-off 340 compared to the MLD group (p = 0.019). All other differences occurred between one or more 341 342 level of disease groups and healthy controls. The controls versus all PAD group comparison yielded differences in 21 of 26 gait variables. Controls were significantly different than patients 343

16

with AI level disease for nine of 26 variables, patients with FP disease for 13 of 26 variables, and
patients with MLD for 19 of 26 variables (Tables VI and VII).

346 Classifying subject group from gait impairments

In the pain free condition, a total of 99 study participants were included in the 347 discriminant analysis. Thirty-three subjects were removed from the total sample of 132 due to 348 the inability to calculate spatiotemporal data or if they were considered to be outliers. Significant 349 connections between the studied gait variables and subject grouping were found (p = 0.011, 350 Wilk's Lambda = 0.478). The classification results indicated the discriminant function correctly 351 classified 56.6% of subjects into the correct subject group. The analysis was most accurate in 352 predicting healthy controls with a 76.0% classification accuracy. This was followed by MLD. 353 354 AI, and FP with a 65.7%, 36.8% and 35.0% classification accuracy respectively. The gait parameter with the most significant contribution to the prediction of subject group in the pain 355 free condition was ankle power generation with a standardized canonical discriminant function 356 coefficient of 0.504. The canonical correlation for this function was 0.629. 357

In the pain condition, a total of 105 study participants were included in the discriminant 358 analysis. Similar to the pain-free conditions, 27 subjects were removed from the total 132 359 subjects due to the inability to calculate spatiotemporal data or if they were considered to be 360 outliers. Significant connections between the studied gait variables and subject grouping were 361 found (p < 0.001, Wilk's Lambda = 0.424). The classification results indicated the discriminant 362 function correctly classified 70.5% of subjects into the correct subject group. The analysis was 363 most accurate in predicting the MLD group with an 88.6% classification accuracy. This was 364 followed by controls, FP, and AI with a classification accuracy of 83.3%, 44.4% and 36.8% 365

17

respectively. The gait parameter with the most significant contribution to the prediction of
subject group in the pain condition was ankle power generation with a standardized canonical
discriminant function coefficient of -0.539. The canonical correlation for this function was 0.658.

369

370 **DISCUSSION**

Our data using advanced biomechanical analyses and standard clinical and quality of life 371 assessments, indicate that different levels of arterial disease present with very different patterns 372 of symptoms affecting the different muscle groups of the lower extremity but produce similar 373 degrees of impairments across all muscle groups of the leg and in the walking patterns and 374 walking distances of claudicating PAD patients. We found that PAD patients with different 375 levels of vascular stenosis/occlusion have very similarly affected gait patterns (as described by 376 377 kinematic, kinetic, and spatiotemporal gait parameters) and walking distances (measured with six-minute walk test) and very similar subjective impairments (measured with WIO and SF-36). 378 379 Patients with AI, FP and MLD disease all had similarly impaired biomechanics, compared to 380 control, around their ankle, knee and hip joints (the muscle groups flexing and extending the ankle, knee and hip are similarly impaired in all PAD groups). None of the investigated 381 biomechanical parameters differed between level of disease groups in the pain free walking 382 condition, with minimal differences occurring in the claudicating condition. Moreover, when 383 trying to determine if patients can be classified according to their level of disease based on gait 384 impairments, and if quality of life information acquired through the WIQ and SF-36, differed 385 across groups of patients with different levels of disease, we found that the model performed 386 well in identifying healthy controls in both the pain (83.3% classification accuracy) and pain 387

18

free (76.0% classification accuracy) conditions and that the model can also accurately classify 388 individuals in the MLD group during the pain condition (88.6% classification accuracy), but had 389 trouble differentiating between PAD subject groups in all other scenarios. Previous work has 390 shown that gait impairments are present from the first steps a PAD patient takes while walking 391 pain-free and are augmented when the patient starts experiencing claudication symptoms [10], 392 393 [11]. This augmentation of walking impairments, especially in what is traditionally the lowest functioning group (MLD)[19], may help explain why the discriminant analysis was more 394 accurate in identifying subject groupings during the pain condition compared to pain-free 395 396 walking. The conclusion of no differences between level of disease groups is reinforced by the fact that all WIQ subscales scores were statistically similar between PAD groups. The SF-36 397 scores were also similar across level of disease groups with the only differences identified being 398 in the subscales of pain between the FP and MLD groups and emotional health between the AI 399 and MLD groups. 400

The results of the current study are not in accord with our hypothesis that different levels 401 of occlusive disease uniquely affect the muscle contributions within the PAD legs and therefore 402 produce distinctive differences in the way claudicating patients walk. Although it may be 403 understandable that claudication produced by occlusions that are similar in hemodynamic 404 significance impair walking distances and quality of life parameters in a similar fashion 405 irrespective of the level of the arterial tree involved, it is difficult to explain how this would also 406 be the case for gait biomechanics. For example, it is difficult to understand how a patient with 407 FP disease presenting with calf claudication can have similarly affected knee and hip 408 biomechanics reflecting similarly compromised thigh and buttock muscle contributions as a 409 patient with AI or MLD disease presenting with calf, thigh and buttock claudication. However, 410

19

this is exactly what our data demonstrate. More specifically all patients with FP disease present 411 with claudication symptoms affecting only their calves while 22 out of 25 AI patients and 34 of 412 49 MLD patients present with claudication symptoms that also affect the thigh and/or buttock 413 musculature, yet gait biomechanics were similar across the three groups. Our findings on level of 414 symptoms confirms the well-known fact that different levels of arterial occlusive disease produce 415 416 symptoms in different muscle groups (calves, thighs, buttocks) of the leg [17], [18] which led us to theorize that different levels of occlusive disease produce ischemia, myopathy and functional 417 compromise of different muscle groups and this would result in distinctive biomechanical 418 419 patterns around the ankle, knee and hip joints. The absence of difference in gait biomechanical patterns was surprising to us and raises several considerations that may explain our findings. 420

A possible explanation may be that AI, FP and MLD all affect the calf and foot of the patient and that the affected foot and calf dominate the biomechanical behavior of the entire leg [42]. This can lead to ankle movement impacting knee and hip mechanics. The stance phase of walking is a closed chain movement, so movement impairments at the ankle must produce a corresponding response (and possibly an impairment) at the knee and/or hip. Additionally, the biarticular nature of certain hamstring, quadricep, and calf muscles, makes it likely that pain in the calves, thigh, or buttocks can impact mechanics at more than one joint.

It is also possible that what we consider to be hemodynamically insignificant (<30% diameter reduction) disease in an arterial segment is a significant contributor to the functional deterioration of the muscles supplied by this arterial segment. This may be because the disease becomes hemodynamically significant (either pressures drop or flow patterns change across the segment) when exercise initiates higher flows through the diseased segment, or because the atherosclerotic plaques (even though they are mild or minimal) produce cytokines, reactive

20

oxygen species and pro-inflammatory products that then reach and adversely affect the 434 corresponding muscle groups [43], [44]. This possibility may be of particular interest since the 435 vast majority of patients with FP disease have atherosclerotic changes in their AI segment 436 (eleven had mild, nine minimal and only three had no occlusive disease) and similarly, the 437 majority of AI patients have atherosclerotic changes in their FP segment (eight had mild, eleven 438 439 minimal and six no femoropopliteal occlusive disease) even though these changes are not hemodynamically significant (<30%). Essentially, one of the most important findings of our 440 study is the very low prevalence of strictly one-level of PAD in claudicating patients. Our data 441 442 suggest that PAD is an atherosclerotic process that presents as multilevel disease with certain arterial segments becoming involved with more hemodynamically significant stenoses than 443 others and this multilevel disease affects the ischemic legs of PAD patients in a multilevel 444 fashion impairing the performance of all leg muscles at the buttock, thigh, and calf level. 445

It is also possible that occlusive disease in a segment of the arterial tree changes the flow 446 patterns in the segment above it and that such disturbed flow patterns may affect the health of the 447 endothelium and all the layers of the arterial wall of the seemingly "normal" arterial segment and 448 the muscles that are perfused by the segment. Related to this is the recently described increase in 449 arterial stiffness in the arteries of PAD patients [45]–[47]. This may be promoted by disturbed 450 flow which stimulates pro-inflammatory responses from endothelial cells and promotes 451 atherosclerotic remodeling of affected arteries through lipid accumulation and elastin 452 degradation[46]. The work by Abraham et al. supports this possibility because it demonstrates a 453 454 substantial decrease in the resting and post exercise transcutaneous oxygen saturation of the skin over the buttocks both in patients with AI disease but also in a large number of patients without 455 AI disease[48], [49]. 456

21

Finally, while it is important to focus on the downstream damage PAD produces to the tissues of 457 the affected lower limbs (due to ischemia and ischemia/reperfusion of the leg) we should also 458 consider the, thus far poorly explored, effects of PAD to the rest of the body (mediated through 459 the activation of metabolic, neural, or inflammatory pathways) as this may also explain some of 460 our findings. In this process the ischemic limb distributes and communicates to the rest of the 461 body, the adverse ischemic events it suffers several times during the day, every time the patient 462 experiences leg ischemia with or without associated claudication symptoms. In this process a 463 patient with FP disease and an ischemic calf can experience pathological changes and decreased 464 465 performance of the ipsilateral non-ischemic thigh or pelvic musculature but also damage to other limbs and organs of the body. This may be an important pathway explaining how PAD can 466 produce the increased morbidity and mortality that is so well documented for PAD patients [5]-467 [7]. The best evidence for a systemic effect of PAD comes from work showing that a single bout 468 of exercise of the PAD legs produces a significant increase of biomarkers of oxidative stress 469 (increased malondialdehyde, consumption of anti-oxidants)[50], increased inflammatory cells 470 (white blood cells and neutrophils)[51], [52] and increased inflammatory cytokines 471 (thromboxane, p-selectin, von Willebrand factor) in the blood and a significant activation of the 472 sympathetic system of PAD patients. Of note, the group of Sinoway and Cauffman have shown 473 in several elegant studies that it takes a few, low-intensity, contractions of the posterior calf 474 muscles of PAD patients to produce significant sympathetic system activation and adverse 475 476 effects on physiologic parameters like the heart rate, blood pressure and coronary and renal artery blood flow [53]–[55]. It is possible that sympathetic system activation by ischemia of the 477 calf can adversely affect the blood flow and the health of the thighs and buttocks. It is likely that 478 479 the increased local production of anaerobic metabolites, reactive oxygen species, and cytokines

22

is a key mediator for the activation of the sympathetic loops that originate in the ischemic leg
[56], [57]. These loops convey the injurious information to the brain, the limb itself, and the rest
of body including limbs and organs [58].

Ankle power generation at push-off was the most significant contributor in determining 483 subject classification (control versus PAD including AI, FP, or MLD) in both the pain and pain 484 free conditions. This is likely due to the importance of the ankle plantarflexors in propelling the 485 individual forward during walking. The plantarflexor muscles contribute approximately 50% of 486 the positive work on the body's center of mass during propulsion and more mechanical power 487 than the hip and knee joints combined [42], [59]–[61]. Similar to previous studies, our results 488 489 indicate patients with PAD display significantly lower power and torque outputs at the ankle compared to healthy controls, with augmented differences after the onset of claudication[10], 490 [11], [14], [15], [62]. However, still no differences between patient groups were observed for 491 this variable. Although all PAD groups had vascular stenosis/occlusion at or above the knee 492 joint, resulting in all groups experiencing inadequate blood flow to the plantarflexor muscles, 493 research has shown oxygen delivery to the muscles is not the only limiting factor in exercise 494 performance for individuals with PAD[63]. Our group and others have extensively described that 495 atherosclerotic blockages produce a state of ischemia and ischemia/reperfusion in the PAD legs 496 which initiates oxidative stress/damage, mitochondrial dysfunction and cytokine upregulation, 497 producing injury to all tissues including muscles, nerves, skin, and subcutaneous tissues [20], 498 [31], [64]. Accumulating injury in the leg leads to progressive damage of muscle structure and 499 500 function which in association with exercise-induced ischemia produce the limitation in walking 501 ability known as claudication. The work of several laboratories including our own has

23

demonstrated that this myopathy is closely related to leg function, daily activity, quality of life
and mortality of PAD patients [7], [65]–[68].

One possible limitation to this study is how level of disease was assigned to each 504 participant. Participants were assigned to a disease group based on the level of the arterial tree 505 which had significant stenosis/occlusion (>30% diameter reduction) as determined by vascular 506 surgeons using computerized tomographic angiographic imaging[35] [36]. Many of these 507 participants had atherosclerotic disease in other areas of the leg but this disease was minimal 508 (less than 10% diameter reduction) or mild (less than 30% diameter reduction). However, given 509 the study results, the authors do not believe this could have changed the results of the study given 510 511 no differences were found between any of the PAD groups.

512 CONCLUSION

Our data using advanced biomechanical analyses and standard clinical and quality of life 513 assessments, indicate that different levels of arterial disease present with symptoms affecting 514 different muscle groups of the lower extremity, but produce similar degrees of dysfunction in all 515 muscle groups of the leg and in the walking patterns, distances, and impairments of PAD patients 516 with claudication. PAD affects claudicating legs in a diffuse manner irrespective of the level of 517 the arterial tree primarily involved. Several pathophysiologic parameters that have to do with the 518 true nature of PAD as a multilevel disease and its complicated hemodynamics, neuropathy, 519 myopathy, and systemic effects will need to be further researched to understand the diffuse 520 manner in which PAD affects the legs of claudicating patients. 521

24

52	2	

Acknowledgements

- 523 This work was supported by grants from the National Institute of Health (R01AG034995,
- 524 R01HD090333, R01AG049868) and the United States Department of Veterans Affairs
- 525 Rehabilitation Research and Development Service (I01RX003266).

25

526 References

- 527 [1] M. H. Criqui and V. Aboyans, "Epidemiology of peripheral artery disease," Circ. Res.,
- vol. 116, no. 9, pp. 1509–1526, 2015.
- 529 [2] W. R. Hiatt *et al.*, "Atherosclerotic peripheral vascular disease symposium II:
- nomenclature for vascular diseases," *Circulation*, vol. 118, no. 25, pp. 2826–2829, 2008.
- [3] H. S. Khaira, R. Hanger, and C. P. Shearman, "Quality of life in patients with intermittent
 claudication," *Eur. J. Vasc. Endovasc. Surg.*, vol. 11, no. 1, pp. 65–69, 1996.
- 533 [4] J. P. Pell, "Impact of intermittent claudication on quality of life," *Eur. J. Vasc. Endovasc.*
- 534 *Surg.*, vol. 9, no. 4, pp. 469–472, 1995.
- 535 [5] M. H. Criqui *et al.*, "Mortality over a period of 10 years in patients with peripheral arterial
 536 disease," *N. Engl. J. Med.*, vol. 326, no. 6, pp. 381–386, 1992.
- 537 [6] A. B. Newman *et al.*, "Ankle-arm index as a marker of atherosclerosis in the
- Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research
 Group.," *Circulation*, vol. 88, no. 3, pp. 837–845, 1993.
- 540 [7] J. R. Thompson *et al.*, "Protein concentration and mitochondrial content in the
- 541 gastrocnemius predicts mortality rates in patients with peripheral arterial disease," *Ann.*
- 542 *Surg.*, vol. 261, no. 3, pp. 605–610, 2015.
- 543 [8] J. D. McCamley *et al.*, "Gait Mechanics Differences Between Healthy Controls and
- Patients With Peripheral Artery Disease After Adjusting for Gait Velocity Stride Length
 and Step Width," *J. Appl. Biomech.*, pp. 1–19, 2018.
- 546 [9] S. A. Myers, B. C. Applequist, J. M. Huisinga, I. I. Pipinos, and J. M. Johanning, "Gait
- 547 kinematics and kinetics are affected more by peripheral arterial disease than age," *J*.
- 548 *Rehabil. Res. Dev.*, vol. 53, no. 2, p. 229, 2016.

- 549 [10] P. Koutakis *et al.*, "Abnormal joint powers before and after the onset of claudication
 550 symptoms," *J. Vasc. Surg.*, vol. 52, no. 2, pp. 340–347, 2010.
- 551 [11] M. M. Scott-Pandorf, N. Stergiou, J. M. Johanning, L. Robinson, T. G. Lynch, and I. I.
- 552 Pipinos, "Peripheral arterial disease affects ground reaction forces during walking,"
- *Journal of Vascular Surgery*, vol. 46, no. 3. pp. 491–499, 2007, doi:
- 554 //doi.org/10.1016/j.jvs.2007.05.029.
- 555 [12] R. G. Crowther, W. L. Spinks, A. S. Leicht, F. Quigley, and J. Golledge, "Relationship
- between temporal-spatial gait parameters, gait kinematics, walking performance, exercise
- 557 capacity, and physical activity level in peripheral arterial disease," J. Vasc. Surg., vol. 45,
- 558 no. 6, pp. 1172–1178, 2007.
- 559 [13] R. Celis, I. I. Pipinos, M. M. Scott-Pandorf, S. A. Myers, N. Stergiou, and J. M.
- Johanning, "Peripheral arterial disease affects kinematics during walking," J. Vasc. Surg.,
- vol. 49, no. 1, pp. 127–132, 2009.
- 562 [14] P. Koutakis, I. I. Pipinos, S. A. Myers, N. Stergiou, T. G. Lynch, and J. M. Johanning,
- ⁵⁶³ "Joint torques and powers are reduced during ambulation for both limbs in patients with ⁵⁶⁴ unilateral claudication," *J. Vasc. Surg.*, vol. 51, no. 1, pp. 80–88, 2010.
- 565 [15] S. R. Wurdeman, P. Koutakis, S. A. Myers, J. M. Johanning, I. I. Pipinos, and N. Stergiou,
 566 "Patients with peripheral arterial disease exhibit reduced joint powers compared to
- velocity-matched controls," *Gait Posture*, vol. 36, no. 3, pp. 506–509, 2012.
- 568 [16] M. R. Jaff et al., "An update on methods for revascularization and expansion of the TASC
- lesion classification to include below-the-knee arteries: a supplement to the Inter-Society
- 570 Consensus for the Management of Peripheral Arterial Disease (TASC II)," Ann. Vasc.
- 571 *Dis.*, vol. 8, no. 4, pp. 343–357, 2015.

572	[17]	J. Olin, B. SM.	C. Proceedings, and	undefined 2010, "Peri	pheral artery disease: current
	L 1	,	0,	,	1 J

- insight into the disease and its diagnosis and management," *Elsevier*, Accessed: Jun. 04,
- 574 2020. [Online]. Available:
- 575 https://www.sciencedirect.com/science/article/pii/S0025619611601742.
- 576 [18] J. F. Lau, M. D. Weinberg, and J. W. Olin, "Peripheral artery disease. Part 1: Clinical
- evaluation and noninvasive diagnosis," *Nature Reviews Cardiology*, vol. 8, no. 7. Nature
 Publishing Group, pp. 405–418, Jul. 31, 2011, doi: 10.1038/nrcardio.2011.66.
- 579 [19] A. Almahameed, "Peripheral arterial disease: Recognition and medical management
- 580 Access Site Management View project," Artic. Clevel. Clin. J. Med., 2006, doi:
- 581 10.3949/ccjm.73.7.621.
- 582 [20] I. I. Pipinos *et al.*, "The myopathy of peripheral arterial occlusive disease: Part 2.
- 583 Oxidative stress, neuropathy, and shift in muscle fiber type," *Vascular and Endovascular*
- *Surgery*, vol. 42, no. 2. pp. 101–112, Apr. 2008, doi: 10.1177/1538574408315995.
- 585 [21] P. Koutakis et al., "Abnormal myofiber morphology and limb dysfunction in
- claudication," J. Surg. Res., vol. 196, no. 1, pp. 172–179, Jun. 2015, doi:
- 587 10.1016/j.jss.2015.02.011.
- 588[22]D. J. Weiss *et al.*, "Oxidative damage and myofiber degeneration in the gastrocnemius of589patients with peripheral arterial disease," *J. Transl. Med.*, vol. 11, no. 1, Sep. 2013, doi:
- 590 10.1186/1479-5876-11-230.
- 591 [23] D. M. Ha et al., "Transforming growth factor-beta 1 produced by vascular smooth muscle
- cells predicts fibrosis in the gastrocnemius of patients with peripheral artery disease," J.
- 593 *Transl. Med.*, vol. 14, no. 1, p. 39, Feb. 2016, doi: 10.1186/s12967-016-0790-3.
- 594 [24] C. J. Mietus et al., "Abnormal Microvascular Architecture, Fibrosis, and Pericyte

595		Characteristics in the Calf Muscle of Peripheral Artery Disease Patients with Claudication
596		and Critical Limb Ischemia," J. Clin. Med., vol. 9, no. 8, p. 2575, Aug. 2020, doi:
597		10.3390/jcm9082575.
598	[25]	G. Cong, X. Cui, R. Ferrari, I. Pipinos, G. CJ. of C., and undefined 2020, "Fibrosis
599		Distinguishes Critical Limb Ischemia Patients from Claudicants in a Transcriptomic and
600		Histologic Analysis," mdpi.com, Accessed: Aug. 28, 2021. [Online]. Available:
601		https://www.mdpi.com/917494.
602	[26]	I. I. Pipinos et al., "Mitochondrial defects and oxidative damage in patients with
603		peripheral arterial disease," Free Radic. Biol. Med., vol. 41, no. 2, pp. 262-269, Jul. 2006,
604		doi: 10.1016/j.freeradbiomed.2006.04.003.
605	[27]	K. I. Makris et al., "Mitochondriopathy of peripheral arterial disease," Vascular, vol. 15,
606		no. 6. pp. 336–343, Nov. 2007, doi: 10.2310/6670.2007.00054.
607	[28]	P. Koutakis, D. Weiss, D. Miserlis, V. SR. biology, and undefined 2014, "Oxidative
608		damage in the gastrocnemius of patients with peripheral artery disease is myofiber type
609		selective," Elsevier, Accessed: Dec. 30, 2020. [Online]. Available:
610		https://www.sciencedirect.com/science/article/pii/S2213231714000858.
611	[29]	P. Koutakis, D. Miserlis, S. M of H. &, and undefined 2015, "Abnormal
612		accumulation of desmin in gastrocnemius myofibers of patients with peripheral artery
613		disease: associations with altered myofiber morphology and density,"
614		journals.sagepub.com, vol. 63, no. 4, pp. 256–269, Apr. 2015, doi:
615		10.1369/0022155415569348.
616	[30]	G. Brevetti, G. Giugliano, L. Brevetti, and W. R. Hiatt, "Inflammation in peripheral artery
617		disease," Circulation, vol. 122, no. 18. pp. 1862–1875, Nov. 02, 2010, doi:

29

618 10.1161/CIRCULATIONAHA.109.918417.

- 619 [31] G. Casale, J. Thompson, L. Carpenter, et al., "Cytokine signature of inflammation
- 620 mediated by autoreactive Th-cells, in calf muscle of claudicating patients with Fontaine
- stage II peripheral artery disease," *Transl Res*, vol. Feb, no. 228, pp. 94-108, 2020, doi
- 622 10.1016/j.trsl.2020.08.008.
- [32] A. W. Gardner, R. M. Ritti-Dias, J. A. Stoner, P. S. Montgomery, K. J. Scott, and S. M.
- Blevins, "Walking economy before and after the onset of claudication pain in patients
- with peripheral arterial disease," J. Vasc. Surg., vol. 51, no. 3, pp. 628–633, 2010.
- 626 [33] V. Aboyans et al., "Measurement and interpretation of the ankle-brachial index: a
- scientific statement from the American Heart Association," *Circulation*, vol. 126, no. 24,
 pp. 2890–2909, 2012.
- [34] L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris, and F. G. R.
- 630 Fowkes, "Inter-society consensus for the management of peripheral arterial disease

631 (TASC II)," J. Vasc. Surg., vol. 45, no. 1, pp. S5–S67, 2007.

- [35] D. Fleischmann, R. L. Hallett, and G. D. Rubin, "CT angiography of peripheral arterial
 disease," *J. Vasc. Interv. Radiol.*, vol. 17, no. 1, pp. 3–26, 2006.
- [36] J. F. Whelan, M. H. Barry, and J. D. Moir, "Color flow Doppler ultrasonography:
- comparison with peripheral arteriography for the investigation of peripheral vascular
 disease," *J. Clin. ultrasound*, vol. 20, no. 6, pp. 369–374, 1992.
- [37] C. L. Vaughan, B. L. Davis, and C. O. Jeremy, "Dynamics of human gait," 1999.
- [38] B. M. Nigg, G. K. Cole, and W. Nachbauer, "Effects of arch height of the foot on angular
- motion of the lower extremities in running," J. Biomech., vol. 26, no. 8, pp. 909–916,
- 640 1993.

641	[39]	M. M. McDermott, K. Liu, J. M. Guralnik, G. J. Martin, M. H. Criqui, and P. Greenland,
	L 1	

- 642 "Measurement of walking endurance and walking velocity with questionnaire: validation
- of the walking impairment questionnaire in men and women with peripheral arterial
- 644 disease," J. Vasc. Surg., vol. 28, no. 6, pp. 1072–1081, 1998.
- [40] J. E. W. Jr and C. D. Sherbourne, "The MOS 36-item short-form health survey (SF-36): I.
- 646 Conceptual framework and item selection," *Med. Care*, pp. 473–483, 1992.
- 647 [41] A. L. Stewart, R. D. Hays, and J. E. Ware, "The MOS short-form general health survey:
- reliability and validity in a patient population," *Med. Care*, vol. 26, no. 7, pp. 724–735,
- 649 1988.
- [42] P. H. Tzu-wei, K. A. Shorter, P. G. Adamczyk, and A. D. Kuo, "Mechanical and energetic
 consequences of reduced ankle plantarflexion in human walking," *J. Exp. Biol.*, p. jeb.
- 652113910, 2015.
- [43] D. Ramji, T. D.-C. & growth factor reviews, and undefined 2015, "Cytokines in
- atherosclerosis: Key players in all stages of disease and promising therapeutic targets,"
- *Elsevier*, Accessed: Aug. 28, 2021. [Online]. Available:
- https://www.sciencedirect.com/science/article/pii/S1359610115000325.
- 657 [44] X. Yang et al., "Oxidative stress-mediated atherosclerosis: Mechanisms and therapies,"
- 658 *Front. Physiol.*, vol. 8, no. AUG, Aug. 2017, doi: 10.3389/FPHYS.2017.00600/FULL.
- [45] M. S.- Atherosclerosis, L. A. and Cardiovascular, and undefined 2007, "Atherosclerosis,
- 661 Accessed: Dec. 29, 2020. [Online]. Available:
- https://www.karger.com/Article/Abstract/96731.
- 663 [46] G. Zahner, M. Gruendl, ... K. S.-J. of vascular, and undefined 2017, "Association

- between arterial stiffness and peripheral artery disease as measured by radial artery
- tonometry," *Elsevier*, Accessed: Dec. 29, 2020. [Online]. Available:
- https://www.sciencedirect.com/science/article/pii/S0741521417315902.
- 667 [47] C. W. Kim et al., "Disturbed flow promotes arterial stiffening through thrombospondin-
- 668 1," *Circulation*, vol. 136, no. 13, pp. 1217–1232, Sep. 2017, doi:
- 669 10.1161/CIRCULATIONAHA.116.026361.
- 670 [48] M. Audonnet, I. Signolet, C. Colas-Ribas, ... M. A.-C., and undefined 2017, "Exercise
- 671 Transcutaneous Oximetry of the Buttocks—External Validation With Computed
- Tomography Angiography—," *jstage.jst.go.jp*, doi: 10.1253/circj.CJ-16-1316.
- 673 [49] P. Abraham *et al.*, "Transcutaneous oxygen pressure measurements on the buttocks during
- exercise to detect proximal arterial ischemia: Comparison with arteriography,"
- 675 *Circulation*, vol. 107, no. 14, pp. 1896–1900, Apr. 2003, doi:
- 676 10.1161/01.CIR.0000060500.60646.E0.
- 677 [50] A. Edwards, ... A. B.-B. journal of, and undefined 1994, "Systemic responses in patients
- 678 with intermittent claudication after treadmill exercise," *ingentaconnect.com*, Accessed:
- 679 Dec. 29, 2020. [Online]. Available:
- https://www.ingentaconnect.com/content/jws/bjs/1994/00000081/00000012/art00009.
- 681 [51] P. Hickman *et al.*, "Exercise in patients with intermittent claudication results in the
- generation of oxygen derived free radicals and endothelial damage," in *Advances in*
- *Experimental Medicine and Biology*, 1994, vol. 361, pp. 565–570, doi: 10.1007/978-1-
- **684 4615-1875-4 96**.
- 685 [52] F. J. Neumann *et al.*, "Activation and decreased deformability of neutrophils after
- intermittent claudication," *Circulation*, vol. 82, no. 3, pp. 922–929, 1990, doi:

32

687 10.1161/01.CIR.82.3.922.

- 688 [53] R. C. Drew, C. A. Blaha, M. D. Herr, R. Cui, and L. I. Sinoway, "Muscle mechanoreflex
- 689 activation via passive calf stretch causes renal vasoconstriction in healthy humans," *Am. J.*
- 690 Physiol. Regul. Integr. Comp. Physiol., vol. 312, no. 6, pp. R956–R964, Jun. 2017, doi:
- 691 10.1152/ajpregu.00322.2016.
- 692 [54] A. Ross, Z. Gao, J. Luck, ... C. B.-A. of vascular, and undefined 2017, "Coronary
- 693 exercise hyperemia is impaired in patients with peripheral arterial disease," *Elsevier*,
- Accessed: Dec. 29, 2020. [Online]. Available:
- https://www.sciencedirect.com/science/article/pii/S0890509616307063?casa_token=TNc6
- 696 pBrG8REAAAAA:Dy6hsLpAizs_tpEzdX7zPsySpRJCdXdiXzfuquKLywHqjLElCcCGZb
- 697 8YAm286zFdabe_JPPFzVs.
- 698 [55] M. D. Muller, R. C. Drew, J. Cui, C. A. Blaha, J. L. Mast, and L. I. Sinoway, "Effect of

699 oxidative stress on sympathetic and renal vascular responses to ischemic exercise,"

700 *Physiol. Rep.*, vol. 1, no. 3, Aug. 2013, doi: 10.1002/phy2.47.

- 701 [56] D. Kim, M. Kuroki, J. Cui, Z. Gao, ... J. L.-A. J. of, and undefined 2020, "Cardiovascular
- Neurohormonal Regulation: Systemic and regional hemodynamic response to activation
- of the exercise pressor reflex in patients with," *ncbi.nlm.nih.gov*, Accessed: Aug. 28,
- 2021. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7191495/.
- 705 [57] M. D. Muller *et al.*, "Oxidative stress contributes to the augmented exercise pressor reflex
- in peripheral arterial disease patients," J. Physiol., vol. 590, no. 23, pp. 6237–6246, Dec.
- 707 2012, doi: 10.1113/JPHYSIOL.2012.241281.
- 708 [58] M. D. Muller, A. B. Reed, U. A. Leuenberger, and L. I. Sinoway, "Physiology in
- medicine: Peripheral arterial disease," J. Appl. Physiol., vol. 115, no. 9, pp. 1219–1226,

- 710 Nov. 2013, doi: 10.1152/JAPPLPHYSIOL.00885.2013.
- 711 [59] A. D. Kuo, J. M. Donelan, and A. Ruina, "Energetic consequences of walking like an
- inverted pendulum: step-to-step transitions," Exerc. Sport Sci. Rev., vol. 33, no. 2, pp. 88–
- 713 97, 2005.
- 714 [60] M. B. Wiggin, G. S. Sawicki, and S. H. Collins, "An exoskeleton using controlled energy
- storage and release to aid ankle propulsion," in *Rehabilitation Robotics (ICORR), 2011*
- 716 *IEEE International Conference on*, 2011, pp. 1–5.
- 717 [61] J. J. Eng and D. A. Winter, "Kinetic analysis of the lower limbs during walking: What
- information can be gained from a three-dimensional model?," J. Biomech., vol. 28, no. 6,
- 719 pp. 753–758, 1995, doi: 10.1016/0021-9290(94)00124-M.
- [62] S. J. Chen *et al.*, "Bilateral claudication results in alterations in the gait biomechanics at
 the hip and ankle joints," *J. Biomech.*, vol. 41, no. 11, pp. 2506–2514, Aug. 2008, doi:
- 722 10.1016/j.jbiomech.2008.05.011.
- 723 [63] T. A. Bauer, E. P. Brass, and W. R. Hiatt, "Impaired muscle oxygen use at onset of
- exercise in peripheral arterial disease," J. Vasc. Surg., 2004, doi:
- 725 10.1016/j.jvs.2004.06.025.
- [64] I. I. Pipinos *et al.*, "The myopathy of peripheral arterial occlusive disease: Part 1.
- Functional and histomorphological changes and evidence for mitochondrial dysfunction,"
- 728 Vascular and Endovascular Surgery, vol. 41, no. 6. pp. 481–489, Dec. 2008, doi:
- 729 10.1177/1538574407311106.
- 730 [65] M. McDermott, K. Liu, L. Tian, ... J. G.-J. of the, and undefined 2012, "Calf muscle
- characteristics, strength measures, and mortality in peripheral arterial disease: a
- 732 longitudinal study," *onlinejacc.org*, Accessed: Dec. 30, 2020. [Online]. Available:

34

733	https://www.onlinejacc.org/content/59/13/1159.abstract.
	1 5 0

- 734 [66] N. S. Evans et al., "Associations of calf skeletal muscle characteristics and peripheral
- nerve function with self-perceived physical functioning and walking ability in persons
- with peripheral artery disease," *Vasc. Med.*, vol. 16, no. 1, pp. 3–11, Feb. 2011, doi:
- 737 10.1177/1358863X10395656.
- 738 [67] A. W. Gardner, D. E. Parker, P. S. Montgomery, S. M. Blevins, A. M. Teague, and A. I.
- 739 Casanegra, "Monitored daily ambulatory activity, inflammation, and oxidative stress in
- patients with claudication," *Angiology*, vol. 65, no. 6, pp. 491–496, 2014, doi:
- 741 10.1177/0003319713489769.
- 742 [68] J. Anderson, F. Epstein, ... C. M.-J. of the, and undefined 2009, "Multifactorial
- 743 determinants of functional capacity in peripheral arterial disease: uncoupling of calf
- muscle perfusion and metabolism," *onlinejacc.org*, Accessed: Dec. 30, 2020. [Online].
- 745 Available: https://www.onlinejacc.org/content/54/7/628.abstract.

1 Table I. Demographic and anthropometric characteristics

	Clinical characteristics	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)
	Age (years)	65.23 ± 9.51	60.67 ± 6.52	63.57 ± 6.69	64.55 ± 6.11
	Body mass (kg)	$\textbf{79.90} \pm \textbf{13.80}$	90.50 ± 14.90	84.20 ± 19.66	$\textbf{87.14} \pm \textbf{17.17}$
	Height (m)	1.74 ± 0.08	1.77 ± 0.09	1.75 ± 0.08	1.75 ± 0.05
	BMI	26.37 ± 3.71	29.03 ± 5.59	27.37 ± 5.08	28.33 ± 5.59
medRxiv preprint o (which was n Th	doi: https://doi.org/10.1101/2022.02.14.22270963; thi ot certified by peer review) is the author/funder, who is article is a US Government work. It is not subject t for use under	s version posted February 15, has granted medRxiv a licens o copyright under 17 USC 105 - a CC0 license.	2022. The copyright holder for e to display the preprint in perp i and is also made available	r this prep <mark>22M 1F</mark> Detuity.	49M
	ABI Most affected limb	> 0.90	$0.63\pm0.15^{\text{b}}$	$0.54\pm0.21^{\text{b}}$	0.41 ± 0.19
	ABI Least affected limb	> 0.90	0.85 ± 0.17^{b}	$0.77\pm0.19^{\text{b}}$	0.62 ± 0.21
_	6MWD (m)		315.5 ± 100.6	320.9 ± 78.4	284.88 ± 103.8

2 a = significantly different compared to aortoiliac group

- 3 b = significantly different compared to multi-level group
- 4 BMI = body mass index
- 5 ABI = ankle brachial index
- 6 6MWD = six-minute walk distance

WIQ subscale scores	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)			
WIQ: Pain	95.71 ± 8.54	44.79 ± 24.98^a	57.07 ± 17.61^{a}	48.72 ± 21.69^a			
WIQ: Distance	92.20 ± 15.99	$24.12 \pm \mathbf{29.84^a}$	$28.29 \pm \mathbf{26.06^a}$	16.74 ± 17.97^a			
WIQ: Speed	$\textbf{80.37} \pm \textbf{18.98}$	36.59 ± 25.04^{a}	$27.93 \pm \mathbf{22.21^a}$	$27.91 \pm \mathbf{25.06^a}$			
WIQ: Stair	$\textbf{92.14} \pm \textbf{15.97}$	$38.89 \pm \mathbf{25.35^a}$	40.22 ± 28.47^a	30.95 ± 24.17^a			
a - significantly different compared to controls							

Table II. Walking Impairment Questionnaire (WIQ) subscale scores 7

8 a = significantly different compared to controls 9 b = significantly different compared to the femoropoliteal group medRxiv preprint doi: https://doi.org/10.1101/2022.02.14.222/10903; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the anthor/funder, who has granted medRxiv allicense to display the preprint in perpetuity. 10 this article is a US condentieve work it is the subject of dom/difference of USOCOS and is also made available UP for use under a CC0 license.

	SF-36 subscale scores	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)
	Physical function	$\textbf{88.67} \pm \textbf{13.89}$	$38.33 \pm \mathbf{16.40^a}$	43.47 ± 16.82^a	$38.27 \pm \mathbf{17.75^a}$
medRxiv preprint (which was Ti	Limitations due to physical health	$91.94 \pm \textbf{26.13}$	$28.13 \pm \mathbf{37.09^a}$	$39.13 \pm \mathbf{33.56^a}$	23.98 ± 34.60^a
	Limitation due to emotional health	89.57 ± 26.70	61.11 ± 41.32^a	52.17 ± 39.98^a	60.54 ± 41.76^{a}
	Energy int doi: https://doi.org/10.1101/2022.02.14.222	86.50 ± 17.39	49.90 ± 21.72^{a}	53.48± 22.00 ^a	44.44 ± 21.38^a
	This article is a US Government work. It is no Emotional Health for	ader, who has granted medRXIV t subject to copyright under 17 L use under a CC0 ligense	ISC 105 and is also made availal 69.83 ± 15.85^{d}	63.22 ± 23.45^{a}	$53.67\pm21.01^{a,b}$
	Pain	$\textbf{82.35} \pm \textbf{13.72}$	52.71 ± 23.97^a	$49.17\pm17.04^{\text{a,d}}$	$65.64\pm22.64^{a,c}$
	Social function	94.83 ± 13.16	66.15 ± 27.46^a	$65.98 \pm \mathbf{26.43^a}$	67.86 ± 24.34^a
	General health	$\textbf{77.35} \pm \textbf{17.37}$	52.71 ± 18.71^{a}	56.96 ± 23.05^a	53.27 ± 15.96^a
12	a = significantly differently	ent compared to	controls		

Table III. Medical Outcomes Study Short Form 36 Health Survey (SF-36) subscale scores

b = significantly different compared to aortoiliac group

c = significantly different compared to femoropopliteal group d = significantly different compared to multi-level group

4

Cait Parameter	Controls	Aortoiliac	Femoropopliteal	Multi-level	All PAD
Gait I al ameter	(n = 35)	(n = 25)	(n = 23)	(n = 49)	(n = 97)
ADT	$\textbf{-0.32}\pm0.10$	$\textbf{-0.24} \pm 0.08^a$	$\textbf{-0.26} \pm 0.11$	$\textbf{-0.25} \pm 0.10^a$	$\textbf{-0.25}\pm0.10^{a}$
APT	1.38 ± 0.19	1.33 ± 0.18	1.31 ± 0.13	1.26 ± 0.22^{a}	1.29 ± 0.19^{a}
KET	0.69 ± 0.21	0.52 ± 0.30	0.52 ± 0.23	0.50 ± 0.24^{a}	0.51 ± 0.25^{a}
KFT	$\textbf{-0.14} \pm 0.15$	$\textbf{-0.21}\pm0.22$	$\textbf{-0.17} \pm 0.16$	$\textbf{-0.21}\pm0.20$	$\textbf{-0.20}\pm0.20$
HET	0.85 ± 0.29	0.69 ± 0.21^{a}	0.59 ± 0.23^{a}	0.64 ± 0.21^{a}	0.64 ± 0.22^a
medRxiv preprint doi: https://doi.org/10.1101/2022	-1.05 ± 0.21	-0.88 ± 0.24 on posted February 15, 2022.	The copyright holder for this preprint	$\textbf{-0.81} \pm 0.23^a$	$\textbf{-0.82}\pm 0.23^{a}$
This article is a US Government we	ork. It is not subject to copyr -0.677seunder 2000	hit under 17 USC 105 and in license. -0.46 ± 0.17^{a}	-0.53 \pm 0.19	$\textbf{-0.42} \pm 0.25^a$	$\textbf{-0.46} \pm 0.22^a$
K 1	$\textbf{-0.91} \pm 0.39$	$\textbf{-0.71} \pm \textbf{0.54}$	$\textbf{-0.62} \pm 0.40$	$\textbf{-0.61} \pm 0.40^a$	$\textbf{-0.64} \pm 0.44^a$
H1	0.41 ± 0.29	0.36 ± 0.29	0.36 ± 0.25	0.38 ± 0.29	0.37 ± 0.28
A2	$\textbf{-0.83} \pm 0.25$	$\textbf{-0.79} \pm 0.27$	$\textbf{-0.78} \pm 0.30$	$\textbf{-0.81} \pm 0.25$	$\textbf{-0.80} \pm 0.26$
K2	0.45 ± 0.22	0.29 ± 0.23^a	0.29 ± 0.14^{a}	0.31 ± 0.18^{a}	0.30 ± 0.19^{a}
H2	$\textbf{-0.84} \pm 0.26$	$\textbf{-0.66} \pm \textbf{0.32}$	$\textbf{-0.62} \pm 0.20^a$	$\textbf{-0.61} \pm 0.28^a$	$\textbf{-0.62} \pm 0.27^a$
A3	2.70 ± 0.69	2.23 ± 0.64^a	1.90 ± 0.45^{a}	1.92 ± 0.64^{a}	2.00 ± 0.61^{a}
K3	$\textbf{-1.19}\pm0.47$	$\textbf{-0.82} \pm 0.23^a$	$\textbf{-0.79} \pm 0.28^a$	$\textbf{-0.78} \pm 0.37^a$	$\textbf{-0.79} \pm 0.32^a$
Н3	0.99 ± 0.23	0.76 ± 0.15^{a}	0.69 ± 0.23^{a}	0.72 ± 0.23^{a}	0.72 ± 0.21^{a}
AROM	18.78 ± 3.66	19.12 ± 4.17	19.29 ± 3.34	20.05 ± 3.44	19.63 ± 3.60
KROM	12.21 ± 3.67	11.49 ± 4.53	11.13 ± 4.80	11.17 ± 5.01	11.25 ± 4.80
HROM	40.10 ± 3.27	36.63 ± 5.37^a	36.33 ± 4.73^{a}	36.51 ± 5.22^a	36.50 ± 5.10^{a}

17 Table IV. Quantitative gait biomechanics during pain free walking

18 a = significantly different compared to controls

19

PAD = peripheral artery disease ADT = ankle dorsiflexor torque, APT = ankle plantarflexor torque, KET = knee extensor torque, KFT = knee flexor torque, HET = hip extensor torque, HFT = hip flexor torque, A1 = ankle power observation during weight accentance, A2 = ankle power

= hip flexor torque, A1 = ankle power absorption during weight acceptance, A2 = ankle power
absorption during single leg support, A3 = ankle power generation during push off, K1 = knee
power absorption during weight acceptance, K2 = knee power generation during single leg support,
K3 = knee power absorption during push off, H1 = hip power generation during weight acceptance,
H2 = Hip power absorption during single leg support, H3 = hip power generation during push off,
AROM = ankle range of motion, KROM = knee range of motion, HROM = hip range of motion

	- abie it spanote	Cantuala	A	E	Malt' land	AUDAD
		Controls	Aortoiliac	remoropopliteal	Multi-level	All PAD
	Gait Parameter					
		(n = 32)	(n = 25)	(n = 21)	(n = 49)	(n = 95)
		()	()		(()
	Step Length (m)	0.73 ± 0.06	0.68 ± 0.08	0.66 ± 0.07^{a}	0.65 ± 0.09^{a}	0.66 ± 0.08^{a}
	Step Senger (m)	0175 - 0100	0.00 - 0.00	0.00 - 0.07	0.00 - 0.09	0.00 - 0.00
	Stride Length					
	Stille Length	1.45 ± 0.11	1.36 ± 0.16	1.33 ± 0.14^{a}	1.29 ± 0.18^{a}	1.32 ± 0.17^{a}
	(m)					
	Velocity (m/s)	1.31 ± 0.14	1.16 ± 0.15^{a}	1.11 ± 0.16^{a}	1.10 ± 0.19^{a}	1.12 ± 0.17^{a}
	Stance Time (s)	0.60 ± 0.07	0.67 ± 0.07^{a}	0.68 ± 0.08^{a}	0.68 ± 0.09^{a}	0.68 ± 0.08^{a}
medRxiv prepri	nt doi: https://doi.org/10.1101/2022.	02.14.22270963; this version	posted February 15, 2022. T	he copyright holder for this preprint		
(which wa	as not certified by peer review) is the This article is a US Government wo	author/funder, who has gran rk. It is not subject to copyrig	ted medRxiv a license to disp ht under 17 USC 105 and is a	lay the preprint in perpetuity.	$1.19 \pm 0.09a$	$1.19 \pm 0.09a$
	Stride Time (3)	for use under a CC0 li	cense. 10 - 0.07	1.21 = 0.09	1.17 = 0.07	1.17 = 0.07
	Swing Time (a)	0.52 ± 0.04	0.51 ± 0.04	0.52 ± 0.02	0.50 ± 0.04	0.51 ± 0.04
	Swing Time (s)	0.32 ± 0.04	0.31 ± 0.04	0.33 ± 0.03	0.30 ± 0.04	0.31 ± 0.04
	G(111 ()	0.07 . 0.02	0.00 . 0.04	0.10 + 0.049	0.10 . 0.049	0.10 . 0.041
	Step width (m)	0.07 ± 0.03	0.09 ± 0.04	0.10 ± 0.04^{a}	0.10 ± 0.04^{a}	0.10 ± 0.04^{a}
	~ .					
	Cadence	107.04 ± 9.71	102.00 ± 7.028	00.02 ± 7.228	101 52 +7 278	101.20 ± 7.478
	(steps/min)	107.94 ± 0.71	102.00± 7.92°	99.92 ± 1.32"	$101.52 \pm 1.57^{\circ}$	$101.30 \pm 7.47^{\circ}$
	(3					

Table V. Spatiotemporal gait measurements during pain free walking

a = significantly different compared to controls PAD = peripheral artery disease

		0		0 1		0
	Gait Parameter	Controls	Aortoiliac	Femoropopliteal	Multi-level	All PAD
		(n = 35)	(n = 25)	(n = 23)	(n = 49)	(n = 9/)
	ADT	-0.32 ± 0.10	-0.22 ± 0.07^{a}	-0.28 ± 0.11	-0.22 ± 0.08^{a}	-0.24 ± 0.09^{a}
	APT	1.38 ± 0.19	1.29 ± 0.20	1.23 ± 0.14	1.16 ± 0.25^{a}	1.21 ± 0.22^{a}
	KET	0.69 ± 0.21	0.56 ± 0.30	0.56 ± 0.25	0.50 ± 0.21^{a}	0.53 ± 0.24^{a}
	KFT	$\textbf{-0.14} \pm 0.15$	$\textbf{-0.20}\pm0.23$	$\textbf{-0.17} \pm 0.20$	$\textbf{-0.17} \pm 0.19$	$\textbf{-0.18} \pm 0.20$
	HET	0.85 ± 0.29	0.69 ± 0.20	0.58 ± 0.24^{a}	0.62 ± 0.22^{a}	0.63 ± 0.22^a
medRxiv preprint o (which was n	doi: https://doi.org/10.4101/2022.02. ot certified by peer review) is the au	14.22270963; this version p thor/funder, who has grante	ostel February 15, 2022 Tr d med Rxiv a license to disp	ne copyright holder for this preprint ay the preprint in perpetuity.	$\textbf{-0.73} \pm 0.24^a$	$\textbf{-0.77} \pm 0.25^a$
In	A1	for use under a CCO lice	-0.46 ± 0.18^{a}	-0.58 ± 0.30^{d}	$-0.36 \pm 0.19^{\mathrm{a,c}}$	$\textbf{-0.44} \pm 0.23^a$
	K 1	$\textbf{-0.91} \pm 0.39$	$\textbf{-0.76} \pm 0.54$	$\textbf{-0.70} \pm 0.46$	$\textbf{-0.58} \pm 0.36^{a}$	$\textbf{-0.65} \pm 0.44^a$
	H1	0.41 ± 0.29	0.38 ± 0.30	0.32 ± 0.25	0.34 ± 0.22	0.35 ± 0.25
	A2	$\textbf{-0.83} \pm 0.25$	$\textbf{-0.81} \pm 0.39$	$\textbf{-0.86} \pm 0.38$	$\textbf{-0.86} \pm 0.28$	$\textbf{-0.84} \pm 0.33$
	К2	0.45 ± 0.22	0.32 ± 0.23	0.33 ± 0.21	0.29 ± 0.18^a	0.31 ± 0.20^a
	H2	$\textbf{-0.84} \pm 0.26$	$\textbf{-0.72} \pm 0.34$	$\textbf{-0.61} \pm 0.27^a$	-0.63 $\pm 0.27^{a}$	$\textbf{-0.65} \pm 0.29^a$
	A3	2.70 ± 0.69	$2.07\pm0.68^{a,d}$	1.71 ± 0.55^{a}	$1.60\pm0.60^{\text{a,b}}$	1.75 ± 0.64^{a}
	K3	$\textbf{-1.19}\pm0.47$	$\textbf{-0.83} \pm 0.30^a$	$\textbf{-0.71} \pm 0.31^a$	$\textbf{-0.69} \pm 0.33^a$	$\textbf{-0.73} \pm 0.32^a$
	Н3	0.99 ± 0.23	0.78 ± 0.24^{a}	0.62 ± 0.27^{a}	0.63 ± 0.23^a	0.66 ± 0.25^a
	AROM	18.78 ± 3.66	20.66 ± 4.82	21.45 ± 3.56	22.06 ± 3.49^{a}	21.56 ± 3.89^a
	KROM	12.21 ± 3.67	12.94 ± 4.54	11.53 ± 5.63	10.78 ± 5.19	11.51 ± 5.17
	HROM	40.10 ± 3.27	36.70 ± 5.37	36.11 ± 5.96^a	$35.14 \pm \mathbf{5.23^a}$	35.77 ± 5.43^a

Table VI. Quantitative gait biomechanics during claudication pain induced walking 32

a = significantly different compared to controls 33

b = significantly different compared to aortoiliac 34

c= significantly different compared to femoropopliteal 35

d = significantly different compared to multi-level 36

PAD = peripheral artery disease ADT = ankle dorsiflexor torque, APT = ankle plantarflexor 37 torque, KET = knee extensor torque, KFT = knee flexor torque, HET = hip extensor torque, HFT 38 = hip flexor torque, A1 = ankle power absorption during weight acceptance, A2 = ankle power 39 absorption during single leg support, A3 = ankle power generation during push, K1 = knee power 40 absorption during weight acceptance, K2 = knee power generation during single leg support, K3 41 = knee power absorption during push off, H1 = hip power generation during weight acceptance, 42 H2 = Hip power absorption during single leg support, H3 = hip power generation during push off 43

	Gait Parameter	Control (n = 32)	Aortoiliac (n = 25)	Femoropopliteal (n = 21)	Multi-level (n = 49)	All PAD (n = 95)
	Step Length (m)	0.73 ± 0.06	0.65 ± 0.09^{a}	0.65 ± 0.08^{a}	0.62 ± 0.09^{a}	0.63 ± 0.09^{a}
	Stride Length (m)	1.45 ± 0.11	1.30 ± 0.18^{a}	1.30 ± 0.17^{a}	1.22 ± 0.19^{a}	1.26 ± 0.18^{a}
	Velocity (m/s)	1.31 ± 0.14	1.11 ± 0.19^{a}	1.08 ± 0.21^{a}	1.04 ± 0.20^{a}	1.07 ± 0.20^a
	Stance Time (s)	0.60 ± 0.07	0.68 ± 0.08^a	0.71 ± 0.08^{a}	0.69 ± 0.10^{a}	0.69 ± 0.09^{a}
	Stride Time (s)	1.12 ± 0.09	1.18 ± 0.10	1.22 ± 0.11^{a}	1.18 ± 0.13	1.19 ± 0.12^{a}
medRxiv prep	Swing Time (s) print doi: https://doi.org/10.1101/2022.00	0.52 ± 0.04 2.14.22270963; this version	0.50 ± 0.04 n posted February 15, 2022	0.52 ± 0.05 . The copyright holder for this preprint	0.50 ± 0.04	0.51 ± 0.04
(which v	vas not certified by peer review) is the a This article is a US Government work	author/funder, who has grar k. It is not subject to copyric for use under a CC0 i	nted medRxiv a license to d ht under 17 USC 105 and icense. 09 ± 0.041	isplay the preprint in perpetuity. s also made available 0.03 a	0.10 ± 0.04^{a}	0.10 ± 0.04^{a}
	Cadence (steps/min)	107.94 ± 8.71	102.00 ± 8.64	99.07 ± 8.76	103.14 ± 15.47	101.94 ± 12.66^a
45	a = significantly di	fferent compa	red to control	S		

Table VII. Spatiotemporal gait measurements during claudication pain induced walking

46 PAD = peripheral artery disease